|
NEURO3d NAMED BY TORNADO INSIDER
AMONG EUROPE’S TOP 100 PRIVATE TECH COMPANIES
Mulhouse,
France, 26th January, 2005:
Neuro3d has been selected as
one of the best-performing and innovative high-tech private companies of Europe
and Israel in the fourth annual Tornado100 list. Neuro3d, headquartered in
Mulhouse, was founded in 2000 and specializes in developing innovative drug
treatments for psychiatric disorders such as schizophrenia, depression or
anxiety.
“We are honored that our drug discovery and development for psychiatric
disorders has been recognized by Tornado Insider in its selection as one of 19
biotech companies of the Top 100 start-ups in Europe,” said Charles Woler,
CEO of Neuro3d. “The award acknowledges the fact that our top-quality team is
in the process of developing superior drug programs to overcome the limitations
of current drug treatments for schizophrenia, depression or anxiety. Being a
2004 Tornado100 Winner will allow us to generate more visibility in the
international marketplace.”
The 2004 Tornado100 list can be found on the website of Tornado Insider (www.tornado-insider.com),
and includes a profile of Neuro3d and the other 99 most promising and innovative
emerging companies in the European IT and biotech sectors.
“The companies Tornado Insider selected are Europe’s technology stars,”
said Niels Valkering, Tornado Insider’s Head of Research. “Combining internal
analysis with advice from industry specialists, we identified the elite of
Europe’s high-tech entrepreneurial vanguard, appreciating excellence both in
innovative, commercial and financial performance. Watch these companies in 2005,
as the technology they are commercializing today will change tomorrow’s trends.”
The selection of the 2004 Tornado100 Winners from thousands of candidates was
judged according to the following criteria:
• Delivering an innovation that shows the promise to
set new standards
• Creating a major new audience
• Supplying a key piece of the ICT infrastructure
• Commanding a significant customer base
• Having the potential to become a global brand or standard
• Influencing a major market
• Receiving a significant amount of funding
• Having a strong valuation for a lucrative exit
• Having a management with previous successful exit experience
The list was announced during the Tornado
Insider/World Financial Symposiums T100 Leadership Forum. This event took place
January 26th, 2005 in London and was a gathering of technology CEOs and CFOs
eager to gain insights on how to lead their enterprise and their careers to more
effective and positive outcomes.
About Neuro3d
Neuro3d SA is a biopharmaceutical company focused on discovery and development
of innovative treatments for psychiatric disorders such as schizophrenia,
depression or anxiety. Neuro3d has a pipeline of compounds with new mechanisms
of action that have the potential to overcome the limitations of current drug
therapies. Neuro3d’s lead compound, the atypical antipsychotic ocaperidone, is
being investigated in two international, double-blind, Phase II trials for
treatment of schizophrenia. Besides ND7001, clinical studies were initiated for
ND1251, a PDE-4 Inhibitor for the treatment of depression in 2004. This
risk-balanced portfolio of clinical-stage products is complemented by multiple
follow-up compounds in research or preclinical studies. The company was founded
in November 2000 and currently has 39 employees. Neuro3d is located in Mulhouse,
France. For more information please visit
www.neuro3d.fr .
Contacts
Neuro3d
Lubor Gaal
Head of Business Development and Licensing
Tel: +33 (0)3 89 36 91 77
Fax: +33 (0)3 89 36 91 78
Mobile: +33 (0)6 71 37 82 99
lgaal@neuro3d.fr
www.neuro3d.fr
Halsin Partners
Mike Sinclair
Director
Tel: +44 (0)870 747 0880
Mobile: +44 (0)7968 022075
msinclair@halsin.com
| 